Y-Intercept (HK)’s Amylyx Pharmaceuticals AMLX Stock Holding History

Y-Intercept (HK)’s Portfolio AMLX Stock Details AMLX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-240,379	Closed	-$1.54M	–	1542
2025 Q2	$1.54M	Buy	+240,379	New	+$1.17M	0.04%	725
2025 Q1	–	Sell	-14,809	Closed	-$56K	–	1167
2024 Q4	$56K	Buy	+14,809	New	+$69.7K	﹤0.01%	1117
2024 Q3	–	Sell	-118,105	Closed	-$224K	–	1275
2024 Q2	$224K	Sell	118,105 -223,412	-65%	-$433K	0.01%	1142
2024 Q1	$970K	Buy	341,517 +292,313	+594%	+$3.82M	0.07%	401
2023 Q4	$724K	Buy	+49,204	New	+$754K	0.07%	444

Other funds holding AMLX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SVCM

Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

FLAM

First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Y-Intercept (HK)'s AMLX Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2025, closing a stake of 240,379 shares — an estimated $1.54M sold.

Y-Intercept (HK) first reported a position in AMLX in Q4 2023 and held it in 5 quarters. The position peaked at $1.54M in Q2 2025. 169 funds tracked by Wall St. Rank hold AMLX as of Q3 2025.

Y-Intercept (HK) reported no remaining Amylyx Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 240,379 Amylyx Pharmaceuticals shares in Q3 2025, an estimated $1.54M.
Y-Intercept (HK) first reported a position in Amylyx Pharmaceuticals in Q4 2023 and held it in 5 quarters.
Y-Intercept (HK)'s Amylyx Pharmaceuticals position peaked at $1.54M in Q2 2025.
169 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.